Recombinant Human B7-2/CD86 Protein

重组人B7-2/CD86蛋白

Activation B7-2 antigen | B70 | B7-2 antigen | B72 | B7-2 | B-lymphocyte activation antigen B7-2 | BU63 | CD28 antigen ligand 2 | CD28LG2B7-2 antigen) | CD86 antigen | CD86 molecule | CD86 | CTLA-4 counter-receptor B7.2 | FUN-1 | LAB72 | MGC34413 | T-lymp

rp217153-10μg

10μg

无动物源

≥95%(SDS-PAGE)

CD86, also known as B-lymphocyte activation antigen B7-2 (referred to as B70), is a member of the cell surface immunoglobulin superfamily. B7-2 exists predominantly as a monomer on cell surfaces and interacts with two co-stimulatory receptors CD28 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) expressed on T cells, and thus induces the signal pathways which regulate T cell activation and tolerance, cytokine production, and the generation of CTL. It is indicated that contacts between B and T helper cells mediated by CD86 encourage signals for the proliferation and IgG secretion of normal B cells and B cell lymphomas. A recent study has revealed that CD86 also promotes the generation of a mature APC repertoire and promotes APC function and survival. CD86 has an important role in chronic hemodialysis, allergic pulmonary inflammation, arthritis, and antiviral responses, and thus is regarded as a promising candidate for immune therapy. Post-translational: Polyubiquitinated; which is promoted by MARCH8 and results in endocytosis and lysosomal degradation.

Immobilized Recombinant Human CD86 Protein (rp217153) at 1.0 μg/mL can bind CD86 Mouse mAb (Ab095464) with the EC50 of 28.0 ng/mL.

重组表达

26.2 kDa

C-His

39.1-61.4 kDa, under reducing conditions; 40.0-57.4 kDa, under non-reducing conditions.

HEK293 Accession #: P42081-3 | HEK293

<1.0 EU/μg

人(Human)

1-239 aa

MGLSNILFVMAFLLSGAAPLKIQAYFNETADLPCQFANSQNQSLSELVVFWQDQENLVLNEVYLGKEKFDSVHSKYMGRTSFDSDSWTLRLHNLQIKDKGLYQCIIHHKKPTGMIRIHQMNSELSVLANFSQPEIVPISNITENVYINLTCSSIHGYPEPKKMSVLLRTKNSTIEYDGIMQKSQDNVTELYDVSISLSVSFPDVTSNMTIFCILETDKTRLLSSPFSIELEDPQPPPDHHHHHHH

Yes

Yes